EA3: Effect of Non-essential Amino Acids on Protein Requirements for Endurance Athletes

• Sponsor: University of Toronto (Other)
• Overall Status: Completed
• CT.gov ID: NCT02874638
• Collaborator: Ajinomoto Co., Inc. (Industry)
• Enrollment: 7
• Arms: 4
• Actual Duration (Months): 16

Study Details

Study Description

Brief Summary

Protein requirements in individuals who participate in endurance-based exercise training have been suggested to be greater than the current recommended dietary allowance (RDA).

The biological value of protein depends on its amino acid composition. Essential amino acids are believed to have main role on whole body protein metabolism. However, it remains to be determined what role non-essential amino acids (NEAA) may have in regulating protein metabolism and contributing to the increased protein requirements after endurance exercise.

The indicator amino acid oxidation (IAAO) method has clarified the individual amino acid requirement in children, normal healthy adult and clinical populations. However, the IAAO method has never been utilized for assessing the effect of NEAA on protein requirements after endurance exercise.

The objective of the current study is to investigate the importance of NEAA for endurance-trained male subjects.

Condition or Disease	Intervention/Treatment	Phase
Increased Metabolic Requirement; Healthy	Dietary Supplement: BASE egg protein; Dietary Supplement: BCAA-enriched egg protein; Dietary Supplement: small amount of essential amino acids; Dietary Supplement: large amount of essential amino acids	N/A

Study Design

• Study Type: Interventional
• Actual Enrollment: 7 participants
• Allocation: Randomized
• Intervention Model: Crossover Assignment
• Masking: Single (Participant)
• Primary Purpose: Basic Science
• Official Title: Effect of Non-essential Amino Acids on Protein Requirements for Endurance Athletes Using Indicator Amino Acid Oxidation Method.
• Actual Study Start Date: Sep 1, 2016
• Actual Primary Completion Date: Aug 1, 2017
• Actual Study Completion Date: Dec 31, 2017

Arms and Interventions

Arm	Intervention/Treatment
Experimental: BASE egg protein 0.8 g/kg/d of BASE protein provided as crystalline amino acid made after egg protein.	Dietary Supplement: BASE egg protein; 0.8 g/kg/d of protein provided as crystalline amino acid modeled after egg protein
Experimental: BCAA-enriched egg protein branched-chain amino acid-enriched egg protein	Dietary Supplement: BCAA-enriched egg protein; BCAA-enriched egg protein provided as crystalline amino acid.
Experimental: small amount of essential amino acids small amount of essential amino acids made after egg protein, which is equivalent to the amount of essential amino acids in BASE	Dietary Supplement: small amount of essential amino acids; essential amino acids modeled after egg protein, provided as crystalline amino acid, which is equivalent to the amount of essential amino acid in BASE egg protein
Experimental: large amount of essential amino acids large amount of essential amino acids made after egg protein, which is equivalent to the amount of amino acids in BCAA	Dietary Supplement: large amount of essential amino acids; essential amino acids modeled after egg protein, provided as crystalline amino acid, which is equivalent to the amount of amino acid in BCAA-enriched egg protein

Outcome Measures

Primary Outcome Measures

1. 13CO2 (carbon dioxide) excretion rate (μmol/kg/h) [at 8 hours after the end of exercise]]

   8 hours after exercise followed by ingesting 13C-labelled phenylalanine and one of 5 different amount of amino acids intake, 13CO2 excretion rate is determined by multiplying the enrichment of 13CO2 in breath measured by Mass spectrometry and CO2 production rate measured by metabolic cart.

Secondary Outcome Measures

1. [13C]phenylalanine oxidation rate (μmol/kg/h) [at 8 hours after the end of exercise]

   8 hours after exercise followed by ingesting 13C-labelled phenylalanine and one of 5 different amount of amino acids intake, 13CO2 excretion rate is determined dividing 13CO2 excretion rate by urinary enrichment of 13C-phenylalanine in breath measured by Mass spectrometry, and CO2 production rate measured by metabolic cart.

Eligibility Criteria

Criteria

• Ages Eligible for Study: 18 Years to 40 Years
• Sexes Eligible for Study: Male
• Accepts Healthy Volunteers: Yes

Inclusion Criteria:

• endurance-trained participants who regularly run more than 40 km/week

• Participants who are categorized at least "very good" based on a study by Shvartz & Reibold, in which VO2peak is used as an index. (i.e. the participants whose VO2peak is ≥57 ml/kg/min (18-24 y), ≥54 ml/kg/min (25-29 y), ≥52 ml/kg/min (30-34 y), ≥49 ml/kg/min (35-39 y)

• Ability to complete the 16-km familiarization run in session 2

Exclusion Criteria:

• Inability to meet health and physical activity guidelines according to the physical activity readiness questionnaire (PAR-Q+)

• Inability to adhere to any of the protocol guidelines (i.e. alcohol, caffeine consumption)

• Regular tobacco use

• Illicit drug use

Contacts and Locations

Locations

No locations specified.

Sponsors and Collaborators

• University of Toronto
• Ajinomoto Co., Inc.

Investigators

• Principal Investigator: Daniel Moore, Ph.D., University of Toronto

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.

• Responsible Party: Daniel Moore, Assistant Professor, University of Toronto
• ClinicalTrials.gov Identifier: NCT02874638
• Other Study ID Numbers: IAAO-EA3
• First Posted: Aug 22, 2016
• Last Update Posted: Apr 1, 2019
• Last Verified: Mar 1, 2019

• Individual Participant Data (IPD) Sharing Statement: No
• Plan to Share IPD: No

Study Results

No Results Posted as of Apr 1, 2019